​

Upstream Bio Stock (NASDAQ:UPB)

RevenueOwnershipFinancialsChart
Upstream Bio by TradingView

Previous Close

$6.69

52W Range

$6.25 - $33.68

50D Avg

$8.96

200D Avg

$17.98

Market Cap

$341.76M

Avg Vol (3M)

$662.17K

Beta

1.11

Div Yield

-

UPB Company Profile

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

52

IPO Date

Oct 11, 2024

Website

UPB Performance

UPB Financial Summary

Dec 25Dec 24Dec 23
Revenue$2.85M$2.37M$2.38M
Operating Income$-160.36M$-77.76M$-40.11M
Net Income$-143.44M$-62.81M$-20.54M
EBITDA$-160.36M$-77.67M$-40.05M
Basic EPS$-2.66$-1.49$-1.05
Diluted EPS$-2.66$-1.49$-1.05

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
PHVSPharvaris N.V.
TERNTerns Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals, Inc.
NVAXNovavax, Inc.
SYRESpyre Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
NTLAIntellia Therapeutics, Inc.
SNDXSyndax Pharmaceuticals, Inc.
WVEWave Life Sciences Ltd.
ZBIOZenas BioPharma, Inc.